Mutis; Tuna

Patent Applications and Registrations

Patent applications and USPTO patent grants for Mutis; Tuna.The latest application filed is for "bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereof".

Company Profile

7.5.14

Mutis; Tuna - Zoeterwoude NL
MUTIS; Tuna - Amsterdam NL
Mutis; Tuna - De Boelelaan NL

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Novel Anticancer Drug Fl118 Formulation In Combination With Immunotherapy For Treatment Of Human Cancer App 20220249464 - Mutis; Tuna ; et al.	2022-08-11
Bispecific Anti-cd37 Antibodies, Monoclonal Anti-cd37 Antibodies And Methods Of Use Thereof App 20220251231 - OOSTINDIE; Simone ; et al.	2022-08-11
Bispecific anti-CD37 antibodies, monoclonal anti-CD37 antibodies and methods of use thereof Grant 11,396,553 - Oostindie , et al. July 26, 2	2022-07-26
Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 App 20210403592 - Ahmadi; Tahamtan ; et al.	2021-12-30
Anti-cd37 Antibodies And Anti-cd20 Antibodies, Compositions And Methods Of Use Thereof App 20210371539 - OOSTINDIE; Simone ; et al.	2021-12-02
Bispecific Anti-cd37 Antibodies, Monoclonal Anti-cd37 Antibodies And Methods Of Use Thereof App 20210355232 - OOSTINDIE; Simone ; et al.	2021-11-18
Bispecific anti-CD37 antibodies, monoclonal anti-CD37 antibodies and methods of use thereof Grant 11,034,772 - Oostindie , et al. June 15, 2	2021-06-15
Immune modulation and treatment of solid tumors with antibodies that specifically bind CD38 Grant 11,021,543 - Ahmadi , et al. June 1, 2	2021-06-01
Bispecific Anti-cd37 Antibodies, Monoclonal Anti-cd37 Antibodies And Methods Of Use Thereof App 20210024647 - OOSTINDIE; Simone ; et al.	2021-01-28
Bispecific Anti-cd37 Antibodies, Monoclonal Anti-cd37 Antibodies And Methods Of Use Thereof App 20200291124 - OOSTINDIE; Simone ; et al.	2020-09-17
Bispecific Anti-cd37 Antibodies, Monoclonal Anti-cd37 Antibodies And Methods Of Use Thereof App 20200270359 - OOSTINDIE; Simone ; et al.	2020-08-27
Combination therapies for heme malignancies with anti-CD38 antibodies and survivin inhibitors Grant 10,668,149 - Doshi , et al.	2020-06-02
Combination therapies with anti-CD38 antibodies Grant 10,604,580 - Lokhorst , et al.	2020-03-31
Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 App 20190144557 - Ahmadi; Tahamtan ; et al.	2019-05-16
Combination Therapies with Anti-CD38 Antibodies App 20170107295 - Lokhorst; Henk M. ; et al.	2017-04-20
Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 App 20170044265 - Ahmadi; Tahamtan ; et al.	2017-02-16
Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 App 20160376373 - Ahmadi; Tahamtan ; et al.	2016-12-29
Combination therapies for heme malignancies with Anti-CD38 antibodies and survivin inhibitors App 20160367663 - Doshi; Parul ; et al.	2016-12-22
Combination Therapies with Anti-CD38 Antibodies App 20160067205 - Lokhorst; Henk M. ; et al.	2016-03-10

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.